Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Unusually active option classes on open January 6th
- Opco lists five potential biotech targets into JPMorgan conference
- Biotech Alert: Searches spiking for these stocks today
- Viking gains ground as Novo Nordisk stumbles, says H.C. Wainwright
- BTIG reiterates Buy on Viking Therapeutics after Novo’s CagriSema ‘underwhelms’